Goldman Sachs’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $47.3M | Buy |
250,321
+75,844
| +43% | +$13.3M | 0.01% | 1616 |
|
|
2025
Q4 | $29.7M | Buy |
174,477
+9,409
| +6% | +$1.44M | ﹤0.01% | 1989 |
|
|
2025
Q3 | $21.8M | Sell |
165,068
-97,546
| -37% | -$11.7M | ﹤0.01% | 2179 |
|
|
2025
Q2 | $27.9M | Sell |
262,614
-88,995
| -25% | -$9.67M | ﹤0.01% | 1833 |
|
|
2025
Q1 | $43.7M | Buy |
351,609
+209,667
| +148% | +$27.4M | 0.01% | 1322 |
|
|
2024
Q4 | $17.5M | Sell |
141,942
-3,130
| -2% | -$369K | ﹤0.01% | 2265 |
|
|
2024
Q3 | $16.2M | Sell |
145,072
-44,897
| -24% | -$4.92M | ﹤0.01% | 2255 |
|
|
2024
Q2 | $20.3M | Buy |
189,969
+3,605
| +2% | +$396K | ﹤0.01% | 1879 |
|
|
2024
Q1 | $22.4M | Sell |
186,364
-52,158
| -22% | -$6.39M | ﹤0.01% | 1737 |
|
|
2023
Q4 | $29.3M | Sell |
238,522
-63,772
| -21% | -$7.96M | 0.01% | 1574 |
|
|
2023
Q3 | $39.1M | Buy |
302,294
+27,895
| +10% | +$3.72M | 0.01% | 1271 |
|
|
2023
Q2 | $34M | Buy |
274,399
+830
| +0.3% | +$112K | 0.01% | 1388 |
|
|
2023
Q1 | $40M | Sell |
273,569
-170,418
| -38% | -$25.2M | 0.01% | 1230 |
|
|
2022
Q4 | $70.7M | Sell |
443,987
-323,146
| -42% | -$47.4M | 0.02% | 912 |
|
|
2022
Q3 | $102M | Sell |
767,133
-205,248
| -21% | -$31.2M | 0.03% | 667 |
|
|
2022
Q2 | $152M | Sell |
972,381
-89,848
| -8% | -$13.8M | 0.04% | 499 |
|
|
2022
Q1 | $165M | Sell |
1,062,229
-248,500
| -19% | -$36.1M | 0.03% | 500 |
|
|
2021
Q4 | $167M | Buy |
1,310,729
+1,133,121
| +638% | +$149M | 0.03% | 530 |
|
|
2021
Q3 | $23.1M | Sell |
177,608
-128,608
| -42% | -$19.4M | ﹤0.01% | 1932 |
|
|
2021
Q2 | $54.4M | Sell |
306,216
-228,069
| -43% | -$39.5M | 0.01% | 1181 |
|
|
2021
Q1 | $87.8M | Sell |
534,285
-45,439
| -8% | -$7.48M | 0.02% | 738 |
|
|
2020
Q4 | $95.7M | Buy |
579,724
+235,908
| +69% | +$35.1M | 0.02% | 644 |
|
|
2020
Q3 | $49M | Sell |
343,816
-225,833
| -40% | -$28M | 0.01% | 1017 |
|
|
2020
Q2 | $62.9M | Sell |
569,649
-75,691
| -12% | -$8.37M | 0.02% | 796 |
|
|
2020
Q1 | $64.4M | Sell |
645,340
-63,714
| -9% | -$8.24M | 0.02% | 707 |
|
|
2019
Q4 | $106M | Buy |
709,054
+48,811
| +7% | +$6.64M | 0.03% | 668 |
|
|
2019
Q3 | $84.6M | Buy |
660,243
+273,255
| +71% | +$36.6M | 0.02% | 763 |
|
|
2019
Q2 | $55.2M | Sell |
386,988
-221,333
| -36% | -$29.7M | 0.02% | 1074 |
|
|
2019
Q1 | $87M | Buy |
608,321
+195,638
| +47% | +$25.5M | 0.03% | 748 |
|
|
2018
Q4 | $51.2M | Sell |
412,683
-102,973
| -20% | -$15.3M | 0.02% | 1076 |
|
|
2018
Q3 | $86.7M | Buy |
515,656
+43,128
| +9% | +$7.42M | 0.02% | 854 |
|
|
2018
Q2 | $81.4M | Sell |
472,528
-259,672
| -35% | -$42.4M | 0.02% | 875 |
|
|
2018
Q1 | $111M | Sell |
732,200
-23,423
| -3% | -$3.44M | 0.03% | 713 |
|
|
2017
Q4 | $102M | Buy |
755,623
+171,174
| +29% | +$23.7M | 0.02% | 788 |
|
|
2017
Q3 | $85.5M | Buy |
584,449
+363,258
| +164% | +$54.9M | 0.02% | 905 |
|
|
2017
Q2 | $34.4M | Sell |
221,191
-99,012
| -31% | -$15.1M | 0.01% | 1521 |
|
|
2017
Q1 | $46.5M | Sell |
320,203
-52,140
| -14% | -$6.79M | 0.01% | 1266 |
|
|
2016
Q4 | $40.6M | Sell |
372,343
-331,713
| -47% | -$36.9M | 0.01% | 1413 |
|
|
2016
Q3 | $85.5M | Buy |
704,056
+108,338
| +18% | +$14.6M | 0.03% | 814 |
|
|
2016
Q2 | $84.2M | Buy |
595,718
+371,721
| +166% | +$54.8M | 0.03% | 770 |
|
|
2016
Q1 | $29.2M | Buy |
223,997
+50,822
| +29% | +$6.33M | 0.01% | 1445 |
|
|
2015
Q4 | $24.3M | Sell |
173,175
-183,425
| -51% | -$25.4M | 0.01% | 1620 |
|
|
2015
Q3 | $47.4M | Sell |
356,600
-32,459
| -8% | -$5.59M | 0.02% | 1094 |
|
|
2015
Q2 | $68.5M | Buy |
389,059
+246,416
| +173% | +$44.3M | 0.02% | 893 |
|
|
2015
Q1 | $24.6M | Buy |
142,643
+96,413
| +209% | +$16.5M | 0.01% | 1607 |
|
|
2014
Q4 | $7.57M | Sell |
46,230
-311
| -0.7% | -$51.6K | ﹤0.01% | 2599 |
|
|
2014
Q3 | $7.47M | Sell |
46,541
-72,202
| -61% | -$11.1M | ﹤0.01% | 2621 |
|
|
2014
Q2 | $17.5M | Sell |
118,743
-20,105
| -14% | -$2.79M | 0.01% | 1904 |
|
|
2014
Q1 | $19.3M | Sell |
138,848
-93,456
| -40% | -$14.1M | 0.01% | 1804 |
|
|
2013
Q4 | $29.4M | Buy |
232,304
+71,644
| +45% | +$7.41M | 0.01% | 1455 |
|
|
2013
Q3 | $14.8M | Buy |
160,660
+76,254
| +90% | +$6.15M | 0.01% | 1865 |
|
|
2013
Q2 | $5.8M | Buy |
+84,406
| New | +$5.16M | ﹤0.01% | 2595 |
|
Other funds holding JAZZ
VPM
VCM
EC
Goldman Sachs's JAZZ Position: Q1 2026 in Review
Goldman Sachs increased its Jazz Pharmaceuticals (JAZZ) stake by 43% in Q1 2026, buying an estimated $13.3M and bringing the position to 250,321 shares worth $47.3M. The position accounts for 0.01% of the portfolio, ranked #1616.
Goldman Sachs first reported a position in JAZZ in Q2 2013 and has held it in 52 quarters since. The position peaked at $167M in Q4 2021. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Goldman Sachs held 250,321 shares of Jazz Pharmaceuticals worth $47.3M as of Q1 2026.
- Goldman Sachs bought 75,844 Jazz Pharmaceuticals shares in Q1 2026, an estimated $13.3M.
- Jazz Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1616 holding.
- Goldman Sachs first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Goldman Sachs's Jazz Pharmaceuticals position peaked at $167M in Q4 2021.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.